196 related articles for article (PubMed ID: 32839836)
1. Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy.
Markus M; Abendroth A; Noureddine R; Paul A; Breitenbuecher S; Virchow I; Schmid KW; Markus P; Schumacher B; Wiesweg M; Wendling J; Mende B; Siveke JT; Schuler M; Kasper S
J Cancer Res Clin Oncol; 2021 Feb; 147(2):579-591. PubMed ID: 32839836
[TBL] [Abstract][Full Text] [Related]
2. A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma.
Maßmann M; Treckmann J; Markus P; Schumacher B; Albers D; Ting S; Mende B; Roehrle J; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Schmid KW; Baba H; Siveke JT; Paul A; Schildhaus HU; Schuler M; Wiesweg M; Kasper S
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5085-5094. PubMed ID: 36334155
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer.
Qi Q; Geng Y; Sun M; Wang P; Chen Z
Pancreatology; 2015; 15(2):145-50. PubMed ID: 25641673
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Gutierrez-Sainz L; Viñal D; Villamayor J; Martinez-Perez D; Garcia-Cuesta JA; Ghanem I; Custodio A; Feliu J
Clin Transl Oncol; 2021 Sep; 23(9):1838-1846. PubMed ID: 33866520
[TBL] [Abstract][Full Text] [Related]
5. Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer.
Geng Y; Qi Q; Sun M; Chen H; Wang P; Chen Z
Eur J Surg Oncol; 2015 Nov; 41(11):1508-14. PubMed ID: 26343824
[TBL] [Abstract][Full Text] [Related]
6. Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
Kamposioras K; Papaxoinis G; Dawood M; Appleyard J; Collinson F; Lamarca A; Ahmad U; Hubner RA; Wright F; Pihlak R; Damyanova I; Razzaq B; Valle JW; McNamara MG; Anthoney A
Acta Oncol; 2022 May; 61(5):583-590. PubMed ID: 35392758
[TBL] [Abstract][Full Text] [Related]
7. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma.
Pointer DT; Roife D; Powers BD; Murimwa G; Elessawy S; Thompson ZJ; Schell MJ; Hodul PJ; Pimiento JM; Fleming JB; Malafa MP
BMC Cancer; 2020 Aug; 20(1):750. PubMed ID: 32782024
[TBL] [Abstract][Full Text] [Related]
9. Preoperative C-reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma.
Ikuta S; Aihara T; Yamanaka N
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e109-e114. PubMed ID: 30632282
[TBL] [Abstract][Full Text] [Related]
10. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer.
Sierzega M; Lenart M; Rutkowska M; Surman M; Mytar B; Matyja A; Siedlar M; Kulig J
Ann Surg Oncol; 2017 Mar; 24(3):808-815. PubMed ID: 27770341
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC).
Xiang ZJ; Hu T; Wang Y; Wang H; Xu L; Cui N
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510138
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
[TBL] [Abstract][Full Text] [Related]
14. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
15. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
Martin HL; Ohara K; Kiberu A; Van Hagen T; Davidson A; Khattak MA
Intern Med J; 2014 Jul; 44(7):676-82. PubMed ID: 24750233
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of postdiagnostic inflammation-based scores in short-term overall survival of advanced pancreatic ductal adenocarcinoma patients.
Xiao Y; Xie Z; Shao Z; Chen W; Xie H; Qin G; Zhao N
Medicine (Baltimore); 2017 Dec; 96(50):e9247. PubMed ID: 29390358
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
Cancer Med; 2014 Apr; 3(2):406-15. PubMed ID: 24519894
[TBL] [Abstract][Full Text] [Related]
19. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy.
Teo M; Mohd Sharial MS; McDonnell F; Conlon KC; Ridgway PF; McDermott RS
Tumori; 2013; 99(4):516-22. PubMed ID: 24326841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
